U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07184788) titled 'G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma' on Sept. 14.
Brief Summary: The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Aggressive B-Cell Lymphoma
Intervention:
DRUG: Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy
Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Gemcitabine (1...